	Application No.	Applicant(s)
	10/619,924	VENKATESH ET AL.
Notice of Allowability	Examiner	Art Unit
	S. Tran	1615
The MAILING DATE of this communication appearable All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHT of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate comministry (GHTS. This application is and MPEP 1308.	n this application. If not included unication will be mailed in due course. THIS
1. This communication is responsive to <u>Request for Reconside</u>	deration filed 06/22/09.	
2. \boxtimes The allowed claim(s) is/are $\underline{1-3,5-9,11-13,15,17-21,24-26,2}$	28,29 and 31-35.	
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	been received. been received in Application	on No
* Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF		
INFORMAL PATENT APPLICATION (PTO-152) which give 5. CORRECTED DRAWINGS (as "replacement sheets") mus	es reason(s) why the oath o	
(a) ☐ including changes required by the Notice of Draftspers	on's Patent Drawing Review	v (PTO-948) attached
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the state of the sheet.	.84(c)) should be written on t	he drawings in the front (not the back) of
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of In	formal Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		ummary (PTO-413), /Mail Date <i>07/07/0</i> 9 .
3. Information Disclosure Statements (PTO/SB/08),		Amendment/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ⊠ Examiner's 9. □ Other	Statement of Reasons for Allowance

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Leigh M. Warren on 07/07/09.

The application has been amended as follows:

Claim 1, last line, after the phrase "the total potassium chloride is released", the phrase ", wherein said plasticized polymer comprises a polymer selected from the group consisting of ethylcellulose, polyvinylpyrrolidone, and hydroxypropyl methylcellulose, wherein said colloidal silicon dioxide is present in an amount of from about 0.1% to about 0.3% by weight of said tablet, wherein said outer membrane coating comprises from about 0.5% to about 5.0% by weight of said compressible coated microcapsules, and wherein said compressible blend is substantially free of lubricants" has been inserted.

Claim 20, last line, after the phrase "the total potassium chloride is released", the phrase ", wherein said plasticized polymer comprises a polymer selected from the group consisting of ethylcellulose, polyvinylpyrrolidone, and hydroxypropyl methylcellulose, wherein said colloidal silicon dioxide is present in an amount of from about 0.1% to about 0.3% by weight of said tablet, wherein said outer membrane coating comprises from about 0.5% to about 5.0% by weight of said compressible coated microcapsules,

and wherein said compressible blend is substantially free of lubricants" has been inserted.

Claim 5, line 1, the phrase "claim 4" has been amended to "claim 1".

Claim 17 has been amended to read as follow:

-- "The process of claim 1 wherein said plasticized polymer comprises ethylcellulose and diethyl phthalate, and wherein said compressible blend comprises about 0.1% to 0.2% by weight colloidal silicon dioxide and not more than about 15% by weight of said microcrystalline cellulose."--

Claim 33, line 2, the phrase ", wherein said tablet is substantially free of lubricants" has been deleted.

Claims 4, 10, 14, 16, 22, 23, 27 and 30 have been cancelled.

The following is an examiner's statement of reasons for allowance:

The closest prior art, Gantt et al., does not teach the claimed compressible blend of microencapsulated potassium chloride that is free of lubricants and comprising 0.1-0.3% colloidal silicon dioxide to obtain a tablet with a friability that does not exceed about 0.3%. The present specification shows unexpected result of about 20-fold improvement in hardness and far superior friability values.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 10/619,924 Page 4

Art Unit: 1615

Claims 1-3, 5-9, 11-13, 15, 17-21, 24-26, 28, 29 and 31-35 are allowed.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Tran whose telephone number is (571) 272-0606. The examiner can normally be reached on M-F 8:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/S. Tran/ Primary Examiner, Art Unit 1615